Adaptive Biotechnologies, a Seattle-based diagnostics maker and dr-g discovery company, told Endpoints News it recently eliminated 6.7% of its workforce as part of its strategic review.
The cuts were across “R&D, commercial, software, and operations functions”.
https://endpts.com/adaptive-biotechnologies-trims-handful-of-jobs-as-strategic-review-nears-completion/